Publications by authors named "Gilson Paluku"

Chronic hepatitis B virus (HBV) infection is one of the leading causes of cirrhosis and liver cancer. In 2019, approximately 1.5 million persons newly acquired chronic HBV infection; among these, 990,000 (66%) were in the World Health Organization (WHO) African Region (AFR).

View Article and Find Full Text PDF

This study summarizes progress made in rolling out COVID-19 vaccinations in the African region in 2022, and analyzes factors associated with vaccination coverage. Data on vaccine uptake reported to the World Health Organization (WHO) Regional Office for Africa by Member States between January 2021 and December 2022, as well as publicly available health and socio-economic data, were used. A negative binomial regression was performed to analyze factors associated with vaccination coverage in 2022.

View Article and Find Full Text PDF

Background: Following the World Health Organization (WHO) recommendation, 38/47 countries have introduced rotavirus vaccines into the program of immunization in the WHO Regional Office for Africa (WHO/AFRO). Initially, two vaccines (Rotarix and Rotateq) were recommended and recently two additional vaccines (Rotavac and Rotasiil) have become available. However, the global supply challenges have increasingly forced some countries in Africa to switch vaccine products.

View Article and Find Full Text PDF

The Democratic Republic of the Congo (DRC) has a high measles incidence despite elimination efforts and has yet to introduce rubella vaccine. We evaluated the performance of a prototype rapid digital microfluidics powered (DMF) enzyme-linked immunoassay (ELISA) assessing measles and rubella infection, by testing for immunoglobulin M (IgM), and immunity from natural infection or vaccine, by testing immunoglobulin G (IgG), in outbreak settings. Field evaluations were conducted during September 2017, in Kinshasa province, DRC.

View Article and Find Full Text PDF

Introduction: as of end 2021, ten different vaccines have received Emergency use listing by the World Health Organisation. The vaccination response to the COVID pandemic started in February 2021 in the WHO African Region. WHO proposed a national coverage target of fully vaccinated population of 40% by the end of December 2021.

View Article and Find Full Text PDF
Article Synopsis
  • Since 2009, the Democratic Republic of Congo has conducted surveillance on rotavirus gastroenteritis, revealing key epidemiological data before the introduction of the vaccine in 2019.
  • Over the studied period, around 4,928 children under age 5 were admitted, with a 60% positivity rate for rotavirus and a peak incidence observed during the dry season from May to September.
  • Genotyping of rotavirus showed that G1P[8] was the most prevalent strain, with variations in genotype distribution based on factors like age and location.
View Article and Find Full Text PDF
Article Synopsis
  • Regular in-service training for healthcare workers is essential to adapt to new vaccines and expand immunization programs to cover all ages, not just infants.
  • A survey of staff in 9 WHO African Region countries revealed that 98.3% recognize significant skill gaps, with a strong need for mid-level management training and refresher courses in various program areas.
  • The findings emphasize the importance of ongoing training and monitoring of staff training status to effectively address these skill gaps and enhance immunization program performance.
View Article and Find Full Text PDF

Background: Rotavirus is the leading cause of acute gastroenteritis (AGE) among children worldwide. Prior to rotavirus vaccine introduction, over one third of AGE hospitalizations in Africa were due to rotavirus. We describe the impact of rotavirus vaccines using data from the African Rotavirus Surveillance Network (ARSN).

View Article and Find Full Text PDF

Background: In 2016, the response to a yellow fever outbreak in Angola and the Democratic Republic of Congo led to a global shortage of yellow fever vaccine. As a result, a fractional dose of the 17DD yellow fever vaccine (containing one fifth [0.1 ml] of the standard dose) was offered to 7.

View Article and Find Full Text PDF

Following the 2010 earthquake, Haiti was at heightened risk for vaccine-preventable diseases (VPDs) outbreaks due to the exacerbation of long-standing gaps in the vaccination program and subsequent risk of VPD importation from other countries. Therefore, partners supported the Haitian Ministry of Health and Population to improve vaccination services and VPD surveillance. During 2010-2016, three polio, measles, and rubella vaccination campaigns were implemented, achieving a coverage > 90% among children and maintaining Haiti free of those VPDs.

View Article and Find Full Text PDF

Background: Haiti had set a national goal to eliminate measles and rubella, as well as congenital rubella syndrome (CRS) by 2010. A 2007-2008 nationwide measles and rubella vaccination campaign targeting 1-19 years, however, reached only 79% of the target population. To assess whether population immunity was adequate to support elimination, we conducted a national serosurvey.

View Article and Find Full Text PDF